drugset
drugset / Trial / NCT02182128

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

NCT02182128 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Confirmation of BIBF 1120 administered from 150 mg twice daily (b.i.d.) to 250 mg b.i.d. as safe and tolerable treatment in Japanese patients with advanced solid tumours, overall safety, pharmacokinetic parameters, biomarkers, and efficacy of BIBF 1120.

Timeline

Start
2006-06
Primary completion
2009-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule 150 mg Oral
Subject Nintedanib Small molecule 250 mg Oral

Indications

neoplasm